SCHEMBL3585852

SCHEMBL3585852

O=C(O)N1CCC(CO)(c2ccc(Br)cc2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.45
ACE2 Q9BYF1 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
POLB P06746 2/20 0.39
ALDH1A1 P00352 2/20 0.39
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
CCR1 P32246 1/20 0.38
HPGD P15428 2/20 0.37
NPC1 O15118 1/20 0.36
MME P08473 1/20 0.36
OPRM1 P35372 1/20 0.35
OPRD1 P41143 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2425376 0.85 HSD11B1 (0.58) HSD11B1CCR1OPRM1MEN1KMT2A
SCHEMBL2425390 0.84 HSD11B1 (0.49) HSD11B1ALDH1A1LMNAOPRM1NPSR1
SCHEMBL3599347 0.82 HSD11B1 (0.44) HSD11B1SMN1; SMN2POLBALDH1A1L3MBTL1
SCHEMBL3589814 0.81 HSD11B1 (0.45) HSD11B1ALDH1A1MEN1KMT2APKLR
SCHEMBL28077549 0.81 HSD11B1 (0.43) HSD11B1CCR1PKLRTACR1
SCHEMBL28077736 0.81 HSD11B1 (0.43) HSD11B1SMN1; SMN2POLBALDH1A1LMNA
SCHEMBL28123227 0.81 TACR1 (0.44) HSD11B1POLBHPGDOPRL1MEN1
SCHEMBL1938618 0.79 RORC (0.48) HSD11B1OPRD1OPRK1TACR1
SCHEMBL4275 0.79 ALDH1A1 (0.38) SMN1; SMN2POLBALDH1A1LMNAMAPK1
SCHEMBL1427539 0.79 CA12 (0.57) ACE2ALDH1A1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383821-B2 NK-1 and serotonin transporter inhibitors BRISTOL-MEYERS SQUIBB COMPANY (US) 2013-02-26 US disclosed
US-20100087434-A1 NK-1 and Serotonin Transporter Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2010-04-08 US disclosed
US-20070249607-A1 NK-1 AND SEROTONIN TRANSPORTER INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-10-25 US disclosed
WO-2007121389-A2 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AS NK-I AND SEROTONIN TRANSPORTER INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087434-A1 NK-1 and Serotonin Transporter Inhibitors SLC6A4, TPH1, SLC6A2 HSD11B1 570/4885ACE2 2046/4885SMN1; SMN2 3244/4885
US-20070249607-A1 NK-1 AND SEROTONIN TRANSPORTER INHIBITORS SLC6A4, TPH1, SLC6A2 HSD11B1 570/4885ACE2 2046/4885SMN1; SMN2 3244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.